The Alzheimer Precision Medicine Initiative
Article type: Review Article
Authors: Hampel, Haralda; b; c; d; * | Vergallo, Andreaa; b; c; d | Perry, Georgee | Lista, Simonea; b; c; d; * | Alzheimer Precision Medicine Initiative (APMI)
Collaborators: AGUILAR, Lisi Flores | BABILONI, Claudio | BALDACCI, Filippo | BENDA, Norbert | BLACK, Keith L. | BOKDE, Arun L.W. | BONUCCELLI, Ubaldo | BROICH, Karl | CACCIOLA, Francesco | CASTRILLO†, Juan | CAVEDO, Enrica | CERAVOLO, Roberto | CHIESA, Patrizia A. | CORVOL, Jean-Christophe | CUELLO, Augusto Claudio | CUMMINGS, Jeffrey L. | DEPYPERE, Herman | DUBOIS, Bruno | DUGGENTO, Andrea | ESCOTT-PRICE, Valentina | FEDEROFF, Howard | FERRETTI, Maria Teresa | FIANDACA, Massimo | FRANK, Richard A. | GARACI, Francesco | GEERTS, Hugo | GIORGI, Filippo S. | GRAZIANI, Manuela | HABERKAMP, Marion | HABERT, Marie-Odile | HAMPEL, Harald | HERHOLZ, Karl | KARRAN, Eric | KIM, Seung H. | KORONYO, Yosef | KORONYO-HAMAOUI, Maya | LANGEVIN, Todd | LEHÉRICY, Stéphane | LISTA, Simone | LORENCEAU, Jean | MANGO, Dalila | MAPSTONE, Mark | NERI, Christian | NISTICÓ, Robert | O’BRYANT, Sid E. | PERRY, George | RITCHIE, Craig | ROSSI, Simone | SAIDI, Amira | SANTARNECCHI, Emiliano | SCHNEIDER, Lon S. | SPORNS, Olaf | TOSCHI, Nicola | VERDOONER, Steven R. | VERGALLO, Andrea | VILLAIN, Nicolas | WELIKOVITCH, Lindsay A. | WOODCOCK, Janet | YOUNESI, Erfan
Affiliations: (Montréal) | (Rome) | (Pisa) | (Bonn) | (Los Angeles) | (Dublin) | (Pisa) | (Bonn) | (Siena) | (Derio) | (Paris) | (Pisa) | (Paris) | (Paris) | (Montréal) | (Las Vegas) | (Gent) | (Paris) | (Rome) | (Cardiff) | (Irvine) | (Zürich) | (Irvine) | (Malvern) | (Rome) | (Berwyn) | (Pisa) | (Roma) | (Bonn) | (Paris) | (Paris) | (Manchester) | (Cambridge) | (Seoul) | (Los Angeles) | (Los Angeles) | (Minneapolis-Saint Paul) | (Paris) | (Paris) | (Paris) | (Rome) | (Irvine) | (Paris) | (Rome) | (Fort Worth) | (San Antonio) | (Edinburgh) | (Siena) | (Rome) | (Siena) | (Los Angeles) | (Bloomington) | (Rome) | (Sacramento) | (Paris) | (Paris) | (Montréal) | (Silver Spring) | (Esch-sur-Alzette) | [a] AXA Research Fund & Sorbonne University Chair, Paris, France | [b] Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l’hôpital, Paris, France | [c] Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France | [d] Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Boulevard de l’hôpital, Paris, France | [e] College of Sciences, One UTSA Circle, The University of Texas at San Antonio, San Antonio, TX, USA | (Montréal) | (Rome) | (Pisa) | (Bonn) | (Los Angeles) | (Dublin) | (Pisa) | (Bonn) | (Siena) | (Derio) | (Paris) | (Pisa) | (Paris) | (Paris) | (Montréal) | (Las Vegas) | (Gent) | (Paris) | (Rome) | (Cardiff) | (Irvine) | (Zürich) | (Irvine) | (Malvern) | (Rome) | (Berwyn) | (Pisa) | (Roma) | (Bonn) | (Paris) | (Paris) | (Manchester) | (Cambridge) | (Seoul) | (Los Angeles) | (Los Angeles) | (Minneapolis-Saint Paul) | (Paris) | (Paris) | (Paris) | (Rome) | (Irvine) | (Paris) | (Rome) | (Fort Worth) | (San Antonio) | (Edinburgh) | (Siena) | (Rome) | (Siena) | (Los Angeles) | (Bloomington) | (Rome) | (Sacramento) | (Paris) | (Paris) | (Montréal) | (Silver Spring) | (Esch-sur-Alzette)
Correspondence: [*] Correspondence to: Harald Hampel, MD, PhD, MA, MSc, and Simone Lista, PhD, AXA Research Fund & Sorbonne University Chair, Sorbonne University, Department of Neurology, Institute of Memory and Alzheimer’s Disease (IM2A), Brain & Spine Institute (ICM), François Lhermitte Building, Pitié-Salpêtrière Hospital, 47 Boulevard de l’hôpital, 75651 Paris CEDEX 13, France. Tel.: +33 1 57 27 46 74; Fax: +33 1 42 16 75 16; E-mails: harald.hampel@icm-institute.org (H. Hampel) and simone.lista@icm-institute.org (S. Lista).
Abstract: Precision medicine (PM) is an evolving scientific renaissance movement implementing key breakthrough technological and scientific advances to overcome the limitations of traditional symptom- and sign-based phenotypic diagnoses and clinical “one-size-fits-all, magic bullet drug development” in these largely heterogeneous target populations. It is a conceptual shift from ineffective treatments for biologically heterogeneous “population averages” to individually-tailored biomarker-guided targeted therapies. PM is defining which therapeutic approach will be the most effective for a specific individual, at a determined disease stage, across multiple medical research fields, including neuroscience, neurology and psychiatry. The launch of the Alzheimer Precision Medicine Initiative (APMI) and its associated cohort program in 2016—facilitated by the academic core coordinating center run by the Sorbonne University Clinical Research Group in Alzheimer Precision Medicine (Sorbonne University GRC n°21 APM)”—is geared at transforming healthcare, conventional clinical diagnostics, and drug development research in Alzheimer’s disease. Ever since the commencement of the APMI, the international interdisciplinary research network has introduced groundbreaking translational neuroscience programs on the basis of agnostic exploratory genomics, systems biology, and systems neurophysiology applying innovative “big data science”, including breakthrough artificial intelligence-based algorithms. Here, we present the scientific breakthrough advances and the pillars of the theoretical and conceptual development leading to the APMI.
Keywords: Alzheimer’s disease, APMI, All of Us Research Program, artificial intelligence, big data, biomarker-guided therapies, precision medicine, systems biology, systems neurophysiology, translational research programs.
DOI: 10.3233/JAD-181121
Journal: Journal of Alzheimer's Disease, vol. 68, no. 1, pp. 1-24, 2019
